LungVax: Lung cancer vaccine
Lung cancer vaccine The 'LungVax' vaccine, developed by researchers from the University of Oxford, the Francis Crick Institute, and University College London, employs technology akin to that of the very effective Oxford..
World-first lung cancer vaccine trials started in seven countries
August 2024: Medical professionals have initiated clinical trials for the first-ever mRNA lung cancer vaccine, which has been praised by specialists for its revolutionary ability to potentially rescue numerous lives. Lung cance..
Lazertinib with amivantamab-vmjw is approved by the USFDA for non-small lung cancer
August 2024: The Food and Drug Administration (FDA) has granted approval for the use of lazertinib (Lazcluze, Janssen Biotech, Inc.) in combination with amivantamab-vmjw (Rybrevant, Janssen Biotech, Inc.) as the initial treatment ..
Neoadjuvant/adjuvant durvalumab is approved by the USFDA for resectable non-small cell lung cancer
August 2024: The Food and Drug Administration has granted approval for the use of durvalumab (Imfinzi, AstraZeneca) in combination with platinum-containing chemotherapy as a neoadjuvant treatment, followed by single-agent durvalum..
Tarlatamab-dlle is granted accelerated approval by FDA for extensive stage small cell lung cancer
May 2024: Tarlatamab-dlle (Imdelltra, Amgen, Inc.) has received fast approval from the Food and Drug Administration for the treatment of extensive stage small cell lung cancer (ES-SCLC) in patients whose illness has worsened after..
Alectinib has been approved by the USFDA as adjuvant treatment for ALK-positive non-small cell lung cancer
Alectinib approved in the treatment of non-small cell lung cancer The Food and Drug Administration (FDA) has approved the drug Alecensa, made by Genentech, Inc. It can be used as an extra treatment for people who have had tumor r..
Amivantamab-vmjw is approved by the USFDA for EGFR exon 20 insertion-mutated non-small cell lung cancer indications
The Food and Drug Administration approved amivantamab-vmjw (Rybrevant, Janssen Biotech, Inc.) in combination with carboplatin and pemetrexed on March 1, 2024. Patients with epidermal growth factor receptor (EGFR) exon 20 insertio..
Osimertinib with chemotherapy is approved by the USFDA for EGFR-mutated non-small cell lung cancer
The Food and Drug Administration approved osimertinib (Tagrisso, AstraZeneca Pharmaceuticals LP) in combination with platinum-based chemotherapy for patients with locally advanced or metastatic non-small cell lung cancer (la/mNSC..
Tepotinib is approved by the USFDA for metastatic non-small cell lung cancer
The Food and Drug Administration officially approved tepotinib (Tepmetko, EMD Serono, Inc.) on February 15, 2024, for adult patients with metastatic non-small cell lung cancer (NSCLC) that had mesenchymal-epithelial transition (M..
Repotrectinib is approved by the USFDA for ROS1-positive non-small cell lung cancer
The Food and Drug Administration authorized repotrectinib (Augtyro, Bristol-Myers Squibb Company) for locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) on November 15, 2023.This FDA approval is the f..